219 related articles for article (PubMed ID: 38526805)
1. OX40/OX40 ligand and its role in precision immune oncology.
Thapa B; Kato S; Nishizaki D; Miyashita H; Lee S; Nesline MK; Previs RA; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Metastasis Rev; 2024 Mar; ():. PubMed ID: 38526805
[TBL] [Abstract][Full Text] [Related]
2. OX40, OX40L and Autoimmunity: a Comprehensive Review.
Webb GJ; Hirschfield GM; Lane PJ
Clin Rev Allergy Immunol; 2016 Jun; 50(3):312-32. PubMed ID: 26215166
[TBL] [Abstract][Full Text] [Related]
3. In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity.
Gao Y; Zhao J; Huang Z; Zhao H; Guo Z; Ma S; Tang X; Song W; Chen X
ACS Biomater Sci Eng; 2023 Jul; 9(7):4108-4116. PubMed ID: 35653749
[TBL] [Abstract][Full Text] [Related]
4. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
Fromm G; de Silva S; Johannes K; Patel A; Hornblower JC; Schreiber TH
J Immunother Cancer; 2018 Dec; 6(1):149. PubMed ID: 30563566
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells.
Reuter D; Staege MS; Kühnöl CD; Föll J
Front Oncol; 2015; 5():242. PubMed ID: 26579494
[TBL] [Abstract][Full Text] [Related]
6. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer.
Deng J; Zhao S; Zhang X; Jia K; Wang H; Zhou C; He Y
Onco Targets Ther; 2019; 12():7347-7353. PubMed ID: 31564917
[TBL] [Abstract][Full Text] [Related]
7. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.
He Y; Zhang X; Jia K; Dziadziuszko R; Zhao S; Deng J; Wang H; Hirsch FR; Zhou C
Transl Lung Cancer Res; 2019 Aug; 8(4):352-366. PubMed ID: 31555511
[TBL] [Abstract][Full Text] [Related]
8. Induction of Antigen-Independent Proliferation of Regulatory T-Cells by TNF Superfamily Ligands OX40L and GITRL.
Kumar P; Arbieva ZH; Maienschein-Cline M; Ganesh BB; Ramasamy S; Prabhakar BS
Methods Mol Biol; 2021; 2248():63-71. PubMed ID: 33185867
[TBL] [Abstract][Full Text] [Related]
9. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD; Augé C; Morris C; Kentner S; Mulgrew K; McGlinchey K; Hair J; Hanabuchi S; Du Q; Damschroder M; Feng H; Eck S; Buss N; de Haan L; Pierce AJ; Park H; Sylwester A; Axthelm MK; Picker L; Morris NP; Weinberg A; Hammond SA
Mol Cancer Ther; 2018 May; 17(5):1024-1038. PubMed ID: 29545330
[TBL] [Abstract][Full Text] [Related]
10. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of a novel anti-OX40 antibody for potent immune activation.
Kuang Z; Jing H; Wu Z; Wang J; Li Y; Ni H; Zhang P; Wu W; Wu M; Zhou S; Qiu X; Wu D; Prinz B; Baruah H; Chen B; Yu M; Liu J
Cancer Immunol Immunother; 2020 Jun; 69(6):939-950. PubMed ID: 32078015
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.
Takeuchi M; Miyoshi H; Nakashima K; Kawamoto K; Yamada K; Yanagida E; Muta H; Moritsubo M; Umeno T; Suzuki T; Seto M; Ohshima K
Ann Hematol; 2020 May; 99(5):1093-1098. PubMed ID: 32157421
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma.
Chen X; Ma H; Mo S; Zhang Y; Lu Z; Yu S; Chen J
Front Immunol; 2022; 13():942154. PubMed ID: 35936015
[TBL] [Abstract][Full Text] [Related]
14. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
Waight JD; Gombos RB; Wilson NS
Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
[TBL] [Abstract][Full Text] [Related]
15. OX40 and OX40L Interaction in Cancer.
Lu X
Curr Med Chem; 2021; 28(28):5659-5673. PubMed ID: 33372866
[TBL] [Abstract][Full Text] [Related]
16. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.
Linch SN; McNamara MJ; Redmond WL
Front Oncol; 2015; 5():34. PubMed ID: 25763356
[TBL] [Abstract][Full Text] [Related]
17. The significance of OX40 and OX40L to T-cell biology and immune disease.
Croft M; So T; Duan W; Soroosh P
Immunol Rev; 2009 May; 229(1):173-91. PubMed ID: 19426222
[TBL] [Abstract][Full Text] [Related]
18. Costimulation through OX40 is crucial for induction of an alloreactive human T-cell response.
Ukyo N; Hori T; Yanagita S; Ishikawa T; Uchiyama T
Immunology; 2003 Jun; 109(2):226-31. PubMed ID: 12757617
[TBL] [Abstract][Full Text] [Related]
19. The TNF-TNFR Family of Co-signal Molecules.
So T; Ishii N
Adv Exp Med Biol; 2019; 1189():53-84. PubMed ID: 31758531
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment.
Chen P; Wang H; Zhao L; Guo H; Zhang L; Zhang W; Sun C; Zhao S; Li W; Zhu J; Yu J; Wu C; He Y
Front Oncol; 2021; 11():713853. PubMed ID: 34900670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]